Advertisement

Clinical Drug Investigation

, Volume 21, Issue 9, pp 597–604 | Cite as

Efficacy and Tolerability of Glimepiride in Daily Practice

A Non-Interventional Observational Cohort Study
  • Gerhard H. Scholz
  • Kerstin Schneider
  • Wolfgang Knirsch
  • Gerhard Becker
Clinical Use

Abstract

Objective

The aim of the present study was to monitor the efficacy and tolerability of glimepiride in daily practice.

Design

An 8-week non-interventional cohort study investigating glimepiride in daily practice.

Setting and Data Collection

4810 general practitioners and hospital physicians were asked to report on demographics and medical history, glimepiride dose, glycated haemoglobin (HbA1c) levels, adverse events and causes of discontinuation of therapy.

Patients

22 045 patients with type 2 diabetes mellitus pretreated with antihyperglycaemic drugs excluding glimepiride and patients not treated with any antihyperglycaemic drug or treated with diet alone. Most patients were either overweight (42.2%) or obese (26.1%).

Results

A total of 29.3% of patients were treated with glimepiride as a first-time antihyperglycaemic drug, whereas in 70.7% of patients pre-existing oral antihyperglycaemic medication was changed to glimepiride monotherapy (69.6%) or continued as combination therapy with glimepiride (30.4%). The initial and final doses were lower in patients who commenced oral antihyperglycaemic therapy (initial 1.3mg, final 1.8mg) compared with patients whose therapy was changed (initial 1.7mg, final 2.4mg). The mean reduction of HbAic was more pronounced in newly treated patients (1.8%) compared with patients changed to glimepiride therapy (1.3%). The most marked reduction in HbAic levels (1.9%) was achieved in obese patients (body mass index ≥ 30 kg/m), treated for the first time with an antihyperglycaemic drug using glimepiride. Bodyweight was reduced on therapy with glimepiride in all patients (1.4kg). With a bodyweight reduction of 2.2kg, this effect was particularly outstanding in obese patients. Adverse events and discontinuation of therapy were observed in 2.3 and 4.9% of patients, respectively, including a hypoglycaemia rate of 0.3%.

Conclusion

This non-interventional study carried out under daily practice conditions confirmed the good efficacy and tolerability of glimepiride in a large number of patients, as documented in previous clinical trials.

Keywords

Adis International Limited Glibenclamide Glimepiride Glipizide Clin Drug Invest 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Müller G. The Molecular mechanism of the insulin-mimetic/ sensitizing activity of the antidiabetic sufonylurea drug amaryl. Mol Med 2000; 6: 907–33PubMedGoogle Scholar
  2. 2.
    Volk A, Maerker E, Rett K, et al. Glimipiride — effects on peripheral insulin sensitivity [abstract]. Diabetologia 2000; 43Suppl. 1: A39Google Scholar
  3. 3.
    Roβkamp R, Wernicke-Panten K, Draeger E. Clinical Profile of the novel sulphonylurea glimepiride. Diabetes Res Clin Pract 1996; 31Suppl.: 33–42CrossRefGoogle Scholar
  4. 4.
    Müller G, Satoh Y, Geise K. Extrapancreatic effects of sulphonylureas —a comparison between glimepiride and conventional sulphonylureas. Diabetes Res Clin Pract 1995; 28Suppl.: 115–37CrossRefGoogle Scholar
  5. 5.
    Massi-Benedetti M, Herz M, Pfeiffer C. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide. Horm Metab Res 1996; 28: 451–5PubMedCrossRefGoogle Scholar
  6. 6.
    SAS, Release 6.11, SAS Institute Inc, Cary, NC; 1996Google Scholar
  7. 7.
    Draeger E. Clinical profile of glimepiride. Diabetes Res Clin Pract 1995; 28Suppl.: 139–46CrossRefGoogle Scholar
  8. 8.
    Draeger KE, Wernicke-Panten K, Lomp H-J, et al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl®): a double-blind comparison with glibenclamide. Horm Metab Res 1996; 28: 419–25PubMedCrossRefGoogle Scholar
  9. 9.
    Winkler F, Teich G, Irsigler K. Österreichische Glimepirid Multicenter-Studie [abstract]. Diabetes Stoffwechsel 1998; 7Suppl.1: 68Google Scholar
  10. 10.
    Glimepirid Anwendungsbeobachtung Österreich 1997/1998. Data on fileGoogle Scholar
  11. 11.
    Glimepirid Anwendungsbeobachtung Holland 1997. Data on fileGoogle Scholar
  12. 12.
    Schneider J. An overview of the safety and tolerance of glimepiride. Horm Metab Res 1996; 28: 413–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Gerhard H. Scholz
    • 1
  • Kerstin Schneider
    • 2
  • Wolfgang Knirsch
    • 2
  • Gerhard Becker
    • 2
  1. 1.Medizinische Klinik und Poliklinik IIIUniversität LeipzigLeipzigGermany
  2. 2.Aventis Pharma Deutschland GmbH, BU DiabetologieBad Soden am TaunusGermany

Personalised recommendations